Healthcare has traditionally been viewed as a domestic services sector, but Australia and New Zealand have both developed significant healthcare exports across multiple categories—medical tourism, telemedicine, hospital management contracts, health technology, and health professional training.

Medical tourism represents the most visible category. Australia attracts approximately 15,000-20,000 international patients annually seeking specialist medical procedures, with total economic impact estimated around $300 million. These patients primarily come from Asia-Pacific countries for procedures including cardiac surgery, orthopedics, cosmetic surgery, and oncology treatment. Australian hospitals combine medical expertise with English-language services in a familiar legal and regulatory environment for patients from regional countries.

New Zealand’s medical tourism sector is smaller, around 5,000-7,000 international patients annually, but growing. The country has positioned around particular specialties including orthopedic surgery, dental work, and fertility treatments. The combination of high-quality care and lower costs than comparable procedures in Australia, the US, or UK creates value propositions for certain patient segments.

The economics of medical tourism are interesting. Private hospitals treating international patients generate revenue that helps sustain services and subsidize infrastructure costs. However, concerns exist about whether prioritizing international patients creates access problems or longer waiting times for domestic patients needing the same specialists and facilities. The data on this is mixed and politically contentious.

Telemedicine exports represent a growing category. Australian specialists provide second opinions and consultations to patients across Asia and the Pacific via video conferencing and digital health platforms. This allows hospitals and doctors to serve international patients without those patients traveling to Australia. The regulatory framework is still evolving—questions around licensing, liability, and cross-border healthcare provision remain partially resolved.

Hospital management and consulting exports are substantial but largely invisible in trade statistics. Australian healthcare administrators and consultants work on hospital projects across the Middle East, Asia, and the Pacific. This includes everything from designing hospital layouts to implementing clinical governance systems to training medical staff. Major Australian healthcare providers maintain international consulting divisions that generate tens of millions in annual revenue.

Health technology represents another export category. Australian and New Zealand companies have developed medical devices, health software, and biotech products sold globally. Companies like Cochlear (hearing implants), Resmed (sleep apnea devices), and Fisher & Paykel Healthcare (respiratory support equipment) generate billions in revenue, with majority of sales to international markets. These are goods exports but closely tied to healthcare expertise.

Pharmaceutical development and clinical trials represent a different kind of healthcare export. Australia conducts significant clinical trial activity for international pharmaceutical companies, particularly in oncology and rare diseases. The combination of well-regulated clinical trial frameworks, diverse patient populations, and English-language operations makes Australia attractive for trials. This generates revenue through trial contracts and builds biotech sector capability.

Health professional training attracts international students to Australian and New Zealand universities studying medicine, nursing, pharmacy, and allied health. This brings direct fee revenue plus economic impact from student spending. It also creates soft power and professional networks as graduates return to home countries. The tension is whether training international students reduces places available for domestic students in constrained professional programs.

Public health expertise is exported through international development programs. Australian and New Zealand public health professionals work on disease surveillance, health systems strengthening, and pandemic response in Pacific Island nations and broader Asia. While partly funded through aid budgets, this develops expertise and relationships that enable commercial healthcare service exports.

Aged care expertise is beginning to be exported. As Asian populations age, demand for aged care services and expertise is growing. Australian companies with aged care experience are forming partnerships in China, Southeast Asia, and other markets to establish facilities and provide training. This represents an early-stage export opportunity that could scale significantly.

Digital health platforms developed in Australia and New Zealand are finding international markets. Patient portals, electronic health records, and telehealth platforms built for domestic markets are being adapted for other countries. The challenges around health data sovereignty, regulatory differences, and language localization are substantial but not insurmountable.

Medical education partnerships represent another dimension. Australian medical schools partner with universities in Malaysia, Singapore, and elsewhere to deliver medical degrees. This generates revenue from international students who may never set foot in Australia while studying, plus supports broader education services exports.

The regulatory environment for healthcare exports remains complex. Each destination market has different regulations around healthcare provision, practitioner registration, and medical device approval. Navigating this complexity requires expertise and creates barriers to entry that protect established providers but limit new entrants.

Insurance and liability considerations affect medical tourism particularly. Questions about what happens if treatment outcomes are poor and whether patients can pursue malpractice claims create risks for both patients and providers. Most international patients sign comprehensive waivers, but legal uncertainty remains.

Quality assurance and accreditation matter for healthcare exports’ credibility. Australian hospitals treating international patients typically seek international accreditation (like JCI) alongside domestic accreditation to provide assurance to patients from different countries. This adds cost but signals quality.

The COVID-19 pandemic disrupted medical tourism significantly when international travel stopped. The sector is recovering but hasn’t yet returned to pre-pandemic volumes. Video consultation services expanded dramatically during the pandemic, accelerating telemedicine export adoption.

Competition for medical tourism comes from Singapore, Thailand, India, and other countries with established healthcare tourism industries. These competitors often offer lower costs than Australia while maintaining quality standards. Australia and New Zealand compete more on specialist expertise, regulatory environment, and cultural familiarity rather than price.

Looking ahead, healthcare exports represent a growth opportunity as regional demand for high-quality healthcare increases with economic development. The constraints are regulatory complexity, professional workforce limitations (exporting healthcare services requires healthcare workers who are already in short supply domestically), and competition from other providers.

For healthcare providers, international services represent revenue diversification and opportunities to maximize utilization of specialist expertise. The risks include reputational damage from poor outcomes, regulatory complications, and potential political backlash if domestic patients face access problems.

Healthcare trade doesn’t feature prominently in trade policy negotiations the way goods and traditional services do, but it represents billions in economic activity and has potential for substantial growth. Whether Australia and New Zealand prioritize developing healthcare exports or focus primarily on domestic health system needs is a policy question that hasn’t been fully resolved.